COMMUNIQUÉS West-GlobeNewswire

Wildflower et son rôle dans l'essor du marché du CBD présentés dans une publication de NetworkNewsWire
15/04/2019
NEW YORK, 15 avr. 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) a annoncé aujourd'hui son apparition dans une rubrique éditoriale publiée par NetworkNewsWire (« NNW »), une [...]
Communiqué de mise à disposition du Document de Référence 2018
15/04/2019
Daix (France), le 15 avril 2019 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de maladies dans les [...]
Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
15/04/2019
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG KONG, April 15, 2019 ( [...]
Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference
15/04/2019
Pratteln, Switzerland, April 15, 2019 - Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function outcomes in idebenone-treated patients [...]
AroCell and Corgenix establish the measurement of Thymidine Kinase 1 using AroCell TK 210 ELISA in a CLIA-lab in the USA
15/04/2019
AroCell AB (AROC NASDAQ Stockholm) announce today, in collaboration with Corgenix (Corgenix Inc., Colorado USA) that the AroCell TK 210 ELISA kit has been validated and approved for Thymidine Kinase 1 (TK1) measurements [...]
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
15/04/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presented In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures [...]
Motif Bio Reports Fiscal Year 2018 Results
15/04/2019
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year [...]
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
14/04/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 DDS-04 Series Cures [...]
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
13/04/2019
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference [...]
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
13/04/2019
- Reduction in serum bile acids and pruritus observed in both populations – - Alagille abstract selected for inclusion in ’Best of ILC’ – - Albireo plans to initiate second A4250 pivotal program in biliary atresia [...]
Genfit: GENFIT to Present Additional Data from the Positive Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress™ 2019
13/04/2019
GENFIT to Present Additional Data from the Positive Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress ™ 2019 Further analysis shows significant improvements [...]
Genfit : GENFIT présentera de nouvelles données issues de l’essai clinique positif de Phase 2 évaluant elafibranor dans la PBC (Cholangite Biliaire Primitive) lors de l’International Liver Congress™ 2019
13/04/2019
GENFIT présentera de nouvelles données issues de l’essai clinique positif de Phase 2 évaluant elafibranor dans la PBC (Cholangite Biliaire Primitive) lors de l’International Liver Congress ™ 2019 Les nouvelles analyses [...]
FastMed and NextCare End Merger Bid
12/04/2019
PHOENIX, April 12, 2019 (GLOBE NEWSWIRE) -- FastMed Urgent Care and NextCare Holdings, Inc. today announced that the companies are halting their plans to merge. The two urgent care leaders reached a definitive agreement [...]
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/04/2019
BOTHELL, Wash., April 12, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]
Teligent, Inc. Management Comments on Recent Market Movements
12/04/2019
BUENA, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today provided commentary on the recent market movements in the price of its [...]
Project HOPE Recognizes Health-Care Heroes
12/04/2019
Awards ceremony honors volunteers who provide lifesaving support Millwood, Va., April 12, 2019 (GLOBE NEWSWIRE) -- Project HOPE is recognizing its top four outstanding volunteers for 2018 – three individuals and one [...]
ImpriMed Raises $4M for Customized Cancer Treatments for Dogs
12/04/2019
Precision medicine lowers the risks of treating lymphoma in dogs and eventually humans PALO ALTO, Calif., April 12, 2019 (GLOBE NEWSWIRE) -- ImpriMed, the cutting edge creator and researcher of custom, precision cancer [...]
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
12/04/2019
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 12 avril 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
Fin du programme de conversion des OC émises en 2018
12/04/2019
Communiqué de Presse Fin du programme de conversion des OC émises en 2018 Dijon, le 12 avril 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un [...]

Pages